Back to Search
Start Over
Novel Therapies in Glioblastoma
- Source :
- Neurology Research International, Vol 2012 (2012), Neurology Research International
- Publication Year :
- 2012
- Publisher :
- Hindawi Limited, 2012.
-
Abstract
- Conventional treatment of glioblastoma has advanced only incrementally in the last 30 years and still yields poor outcomes. The current strategy of surgery, radiation, and chemotherapy has increased median survival to approximately 15 months. With the advent of molecular biology and consequent improved understanding of basic tumor biology, targeted therapies have become cornerstones for cancer treatment. Many pathways (RTKs, PI3K/AKT/mTOR, angiogenesis, etc.) have been identified in GBM as playing major roles in tumorigenesis, treatment resistance, or natural history of disease. Despite the growing understanding of the complex networks regulating GBM tumors, many targeted therapies have fallen short of expectations. In this paper, we will discuss novel therapies and the successes and failures that have occurred. One clear message is that monotherapies yield minor results, likely due to functionally redundant pathways. A better understanding of underlying tumor biology may yield insights into optimal targeting strategies which could improve the overall therapeutic ratio of conventional treatments.
- Subjects :
- Chemotherapy
business.industry
Tumor biology
Angiogenesis
medicine.medical_treatment
Review Article
Bioinformatics
medicine.disease_cause
medicine.disease
Natural history of disease
lcsh:RC346-429
Cancer treatment
Neurology
Medicine
Neurology (clinical)
business
Carcinogenesis
PI3K/AKT/mTOR pathway
lcsh:Neurology. Diseases of the nervous system
Glioblastoma
Subjects
Details
- Language :
- English
- ISSN :
- 20901860 and 20901852
- Volume :
- 2012
- Database :
- OpenAIRE
- Journal :
- Neurology Research International
- Accession number :
- edsair.doi.dedup.....b45ad746d3532b6bb072568410dd3b2f